Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Treatment of neurological disorders with intravenous immunoglobulin (IVIg) is an increasing feature of our practice for an expanding range of indications. For some there is evidence of benefit from randomised controlled trials, whereas for others evidence is anecdotal. The relative rarity of some of the disorders means that good randomised control trials will be difficult to deliver. Meanwhile, the treatment is costly and pressure to "do something" in often distressing disorders considerable. This review follows a 1 day meeting of the authors in November 2000 and examines current evidence for the use of IVIg in neurological conditions and comments on mechanisms of action, delivery, safety and tolerability, and health economic issues. Evidence of efficacy has been classified into levels for healthcare interventions (tables 1 and 2).

Original publication

DOI

10.1136/jnnp.72.4.440

Type

Journal article

Journal

Journal of neurology, neurosurgery, and psychiatry

Publication Date

04/2002

Volume

72

Pages

440 - 448

Addresses

Sobell Department of Neurophysiology, Institute of Neurology, Queen Square, London WCIN 3BG, UK. wiles@cf.ac.uk

Keywords

Humans, Myositis, Multiple Sclerosis, Stiff-Person Syndrome, Peripheral Nervous System Diseases, Vasculitis, Immunoglobulins, Intravenous, Evidence-Based Medicine, Health Care Costs, Drug Costs, Randomized Controlled Trials as Topic